Differential gene expression profiling of human epidermal growth factor receptor 2-overexpressing mammary tumor
Yan Wang
Key Laboratory of Protein Chemistry and Developmental Biology of the Education Ministry of China, College of Life Science, Hunan Normal University, Changsha 410081, China
These authors contributed equally to this work
Search for more papers by this authorHaining Peng
Key Laboratory of Protein Chemistry and Developmental Biology of the Education Ministry of China, College of Life Science, Hunan Normal University, Changsha 410081, China
These authors contributed equally to this work
Search for more papers by this authorYingli Zhong
Key Laboratory of Protein Chemistry and Developmental Biology of the Education Ministry of China, College of Life Science, Hunan Normal University, Changsha 410081, China
These authors contributed equally to this work
Search for more papers by this authorDaiqiang Li
Department of Pathology, the Second Xiangya Hospital, Central South University, Changsha 410011, China
Search for more papers by this authorMi Tang
Department of Pathology, the Second Xiangya Hospital, Central South University, Changsha 410011, China
Search for more papers by this authorXiaofeng Ding
Key Laboratory of Protein Chemistry and Developmental Biology of the Education Ministry of China, College of Life Science, Hunan Normal University, Changsha 410081, China
Search for more papers by this authorCorresponding Author
Jian Zhang
Key Laboratory of Protein Chemistry and Developmental Biology of the Education Ministry of China, College of Life Science, Hunan Normal University, Changsha 410081, China
Model Organism Division, E-Institutes of Shanghai Universities, Shanghai Second Medical University, Shanghai 200025, China
*Corresponding author: Tel/Fax, 86-731-8872792; E-mail, [email protected]Search for more papers by this authorYan Wang
Key Laboratory of Protein Chemistry and Developmental Biology of the Education Ministry of China, College of Life Science, Hunan Normal University, Changsha 410081, China
These authors contributed equally to this work
Search for more papers by this authorHaining Peng
Key Laboratory of Protein Chemistry and Developmental Biology of the Education Ministry of China, College of Life Science, Hunan Normal University, Changsha 410081, China
These authors contributed equally to this work
Search for more papers by this authorYingli Zhong
Key Laboratory of Protein Chemistry and Developmental Biology of the Education Ministry of China, College of Life Science, Hunan Normal University, Changsha 410081, China
These authors contributed equally to this work
Search for more papers by this authorDaiqiang Li
Department of Pathology, the Second Xiangya Hospital, Central South University, Changsha 410011, China
Search for more papers by this authorMi Tang
Department of Pathology, the Second Xiangya Hospital, Central South University, Changsha 410011, China
Search for more papers by this authorXiaofeng Ding
Key Laboratory of Protein Chemistry and Developmental Biology of the Education Ministry of China, College of Life Science, Hunan Normal University, Changsha 410081, China
Search for more papers by this authorCorresponding Author
Jian Zhang
Key Laboratory of Protein Chemistry and Developmental Biology of the Education Ministry of China, College of Life Science, Hunan Normal University, Changsha 410081, China
Model Organism Division, E-Institutes of Shanghai Universities, Shanghai Second Medical University, Shanghai 200025, China
*Corresponding author: Tel/Fax, 86-731-8872792; E-mail, [email protected]Search for more papers by this authorThis work was supported in part by the grants from the National Natural Science Foundation of China (20335020 and 90608006), the Program for Changjiang Scholars and Innovative Research Team in University (No. IRT0445), and the Science and Technology Department of Hunan Province (No. 2006JT2008)
Abstract
Human epidermal growth factor receptor 2 (HER2) is highly expressed in approximately 30% of breast cancer patients, and substantial evidence supports the relationship between HER2 overexpression and poor overall survival. However, the biological function of HER2 signal transduction pathways is not entirely clear. To investigate gene activation within the pathways, we screened differentially expressed genes in HER2-positive mouse mammary tumor using two-directional suppression subtractive hybridization combined with reverse dot-blotting analysis. Forty genes and expressed sequence tags related to transduction, cell proliferation/growth/apoptosis and secreted/extracellular matrix proteins were differentially expressed in HER2-positive mammary tumor tissue. Among these, 19 were already reported to be differentially expressed in mammary tumor, 11 were first identified to be differentially expressed in mammary tumor in this study but were already reported in other tumors, and 10 correlated with other cancers. These genes can facilitate the understanding of the role of HER2 signaling in breast cancer.
References
- 1 Dendukuri N, Khetani K, McIsaac M, Brophy J. Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis. CMAJ 2007, 176: 1429–1434.
- 2 Kauraniemi P, Kallioniemi A. Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer. Endocr Relat Cancer 2006, 13: 39–49.
- 3 Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235: 177–182.
- 4 Van De Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, Nusse R. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 1988, 319: 1239–1245.
- 5 Guinebretiere JM, Menet E, Tardivon A, Cherel P, Vanel D. Normal and pathological breast, the histological basis. Eur J Radiol 2005, 54: 6–14.
- 6 Wang HT, Ma FL, Ma XB, Han RF, Zhang YB, Chang JW. Differential gene expression profiling in aggressive bladder transitional cell carcinoma compared to the adjacent microscopically normal urothelium by microdissection-SMART cDNA PCR-SSH. Cancer Biol Ther 2006, 5: 104–110.
- 7 Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29: e45.
- 8 Bustin SA. Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems. J Mol Endocrinol 2002, 29: 23–39.
- 9 Chan TO, Rittenhouse SE, Tsichlis PN. AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. Annu Rev Biochem 1999, 68: 965–1014.
- 10
Stoesz SP,
Friedl A,
Haag JD,
Lindstrom MJ,
Clark GM,
Gould MN.
Heterogeneous expression of the lipocalin NGAL in primary breast cancers.
Int J Cancer
1998, 79: 565–572.
10.1002/(SICI)1097-0215(19981218)79:6<565::AID-IJC3>3.0.CO;2-F CAS PubMed Web of Science® Google Scholar
- 11 Cheng KW, Lahad JP, Gray JW, Mills GB. Emerging role of RAB GTPases in cancer and human disease. Cancer Res 2005, 65: 2516–2519.
- 12 Sers C, Emmenegger U, Husmann K, Bucher K, Andres AC, Schafer R. Growth-inhibitory activity and downregulation of the class II tumor-suppressor gene H-rev1 07 in tumor cell lines and experimental tumors. J Cell Biol 1997, 136: 935–944.
- 13 Andreu P, Colnot S, Godard C, Laurent-Puig P, Lamarque D, Kahn A, Perret C et al. Identification of the IFITM family as a new molecular marker in human colorectal tumors. Cancer Res 2006, 66: 1949–1955.
- 14 Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy. Oncologist 1998, 3: 237–252.
- 15 Bellacosa A, Kumar CC, Di Cristofano A, Testa JR. Activation of AKT kinases in cancer: Implications for therapeutic targeting. Adv Cancer Res 2005, 94: 29–86.
- 16 Woodgett JR. Recent advances in the protein kinase B signaling pathway. Curr Opin Cell Biol 2005, 17: 150–157.
- 17 Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1999, 13: 2905–2927.
- 18 Scheid MP, Woodgett JR. PKB/AKT: Functional insights from genetic models. Nat Rev Mol Cell Biol 2001, 2: 760–768.
- 19 Delord JP, Allal C, Canal M, Mery E, Rochaix P, Hennebelle I, Pradines A et al. Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma. Ann Oncol 2005, 16: 1889–1897.
- 20 Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002, 296: 1655–1657.
- 21 Desai KV, Xiao N, Wang W, Gangi L, Greene J, Powell JI, Dickson R et al. Initiating oncogenic event determines gene-expression patterns of human breast cancer models. Proc Natl Acad Sci USA 2002, 99: 6967–6972.
- 22 Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003, 100: 8418–8423.
- 23 Cheng JM, Ding M, Aribi A, Shah P, Rao K. Loss of RAB25 expression in breast cancer. Int J Cancer 2006, 118: 2957–2964.
- 24 Osawa Y, Nagaki M, Banno Y, Brenner DA, Nozawa Y, Moriwaki H, Nakashima S. Expression of the NF-κB target gene X-ray-inducible immediate early response factor-1 short enhances TNF-α-induced hepatocyte apoptosis by inhibiting Akt activation. J Immunol 2003, 170: 4053–4060.
- 25 Rocher G, Letourneux C, Lenormand P, Porteu F. Inhibition of B56-containing protein phosphatase 2As by the early response gene IEX-1 leads to control of Akt activity. J Biol Chem 2007, 282: 5468–5477.
- 26 Maroulakou IG, Oemler W, Naber SP, Tsichlis PN. Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. Cancer Res 2007, 67: 167–77.
- 27 Hajnal A, Klemenz R, Schafer R. Subtraction cloning of H-rev 107, a gene specifically expressed in H-ras resistant fibroblasts. Oncogene 1994, 9: 479–490.
- 28 Husmann K, Sers C, Fietze E, Mincheva A, Lichter P, Schafer R. Transcriptional and translational downregulation of H-REV107, a class II tumor suppressor gene located on human chromosome 11q11-12. Oncogene 1998, 17: 1305–1312.
- 29 Komatsu M, Chiba T, Tatsumi K, Iemura S, Tanida I, Okazaki N, Ueno T et al. A novel protein-conjugating system for Ufm1, a ubiquitin-fold modifier. EMBO J 2004, 23: 1977–1986.
